title: Emerging trends in invasive and noninvasive isolates of Streptococcus agalactiae in a Latin American hospital: a 17-year study.
abstract: BACKGROUND
  Streptococcus agalactiae or group B Streptococcus (GBS) has been recognized as a lethal pathogen in neonates worldwide. S. agalactiae infections also severely affect pregnant women and immunosuppressed adults with substantial attributable morbidity and mortality. However, in Latin America, studies on the epidemiology and behaviour of S. agalactiae infections remain limited.
  
  
  METHODS
  To better understand the behaviour of S. agalactiae infections in our region, we conducted a retrospective study to phenotypically describe S. agalactiae isolates collected in one of the largest hospitals in Colombia at two time periods: 1994-2001 and 2004-2012. The isolates were identified by biochemical analysis and tested for antimicrobial susceptibility.
  
  
  RESULTS
  In 1994-2001 a total of 201 S. agalactiae isolates were found in urine 38.3%, vaginal exudates 27.8%, soft tissue 12.9%, and blood 8.5%. Susceptibility to ampicillin or penicillin was 94% whereas resistance to erythromycin and clindamycin were 2.8% and 5.2% respectively. In total 46 culture-positive cases of invasive infections were reported, 11 (24%) in neonates and 35 (76%) in adults. In 2004-2012 a total of 671 isolates were found in urine 47.8%, vaginal exudates 32.6%, soft tissue 2.7% and blood 9%. Susceptibility rates to ampicillin and penicillin were 98% whereas resistance to erythromycin and clindamycin were 12.5% and 9.4%. A total of 95 severe infections were reported: 12 (12.6%) were in neonates, 5 (5.3%) in children and 78 (82.1%) in adults. Over the 17-year study period the averaged prevalence of invasive S. agalactiae isolates was 17.4%. The estimated incidence for neonatal infections was 1.34 per 1000 livebirths (0.99 × 1000 livebirths for early- onset disease and 0.35 × 1000 livebirths for late- onset disease) whereas for non-pregnant adults the estimated incidence was 0.75 × 1000 admissions.
  
  
  CONCLUSIONS
  A remarkable increase in bloodstream infections in immunosuppressed adults and a shift to early neonatal S. agalactiae infections were seen over time. We also found an increase in S. agalactiae resistance to erythromycin and clindamycin during the study period, and the emergence of penicillin-nonsusceptible isolates. Our findings are consistent with the global trends described elsewhere, reinforcing the need for S. agalactiae control measures in our region.
authors.affiliation: Department of Biomedical Sciences, Santiago de Cali University, Cali, Colombia. mpcrespo@usc.edu.co.
authors.forename: Maria del Pilar
authors.initials: Mdel P
authors.lastname: Crespo-Ortiz
authors.forename: Claudia Rocio
authors.initials: CR
authors.lastname: Castañeda-Ramirez
authors.forename: Monica
authors.initials: M
authors.lastname: Recalde-Bolaños
authors.forename: Juan Diego
authors.initials: JD
authors.lastname: Vélez-Londoño
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D003105:Colombia / Q000453:epidemiology; D003430:Cross-Sectional Studies; D024881:Drug Resistance, Bacterial; D005260:Female; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000453:epidemiology / Q000382:microbiology*; D013292:Streptococcus agalactiae / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
references.citation: J Clin Microbiol. 2004 Sep;42(9):4214-22
references.pmid: 15365014
references.citation: Bol Med Hosp Infant Mex. 1990 Mar;47(3):146-52
references.pmid: 2193651
references.citation: Acta Obstet Gynecol Scand. 2010;89(2):250-5
references.pmid: 19916889
references.citation: Antimicrob Agents Chemother. 2008 Aug;52(8):2890-7
references.pmid: 18490507
references.citation: Int J Infect Dis. 2012 Mar;16(3):e182-6
references.pmid: 22236484
references.citation: J Antimicrob Chemother. 2013 Mar;68(3):539-42
references.pmid: 23111853
references.citation: J Pediatr. 1973 Apr;82(4):707-18
references.pmid: 4572747
references.citation: Rev Argent Microbiol. 2004 Apr-Jun;36(2):63-7
references.pmid: 15473046
references.citation: Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F140
references.pmid: 11330249
references.citation: BMC Infect Dis. 2011 May 25;11:149
references.pmid: 21612629
references.citation: Braz J Infect Dis. 2002 Apr;6(2):55-62
references.pmid: 11980605
references.citation: BMC Microbiol. 2013 Feb 18;13:41
references.pmid: 23419028
references.citation: Pediatrics. 2011 May;127(5):817-26
references.pmid: 21518717
references.citation: Clin Infect Dis. 2009 Jul 1;49(1):85-92
references.pmid: 19480572
references.citation: BMC Infect Dis. 2010 Nov 24;10:336
references.pmid: 21106080
references.citation: J Microbiol Immunol Infect. 2006 Oct;39(5):396-401
references.pmid: 17066202
references.citation: Clin Infect Dis. 2012 Jul;55(1):91-102
references.pmid: 22523262
references.citation: J Infect Dis. 2000 Jul;182(1):168-73
references.pmid: 10882594
references.citation: Rev Argent Microbiol. 2010 Jul-Sep;42(3):203-7
references.pmid: 21180391
references.citation: Infection. 2008 Mar;36(2):100-11
references.pmid: 18193384
references.citation: Infect Dis Obstet Gynecol. 2012;2012:913603
references.pmid: 22675244
references.citation: Ann Intern Med. 1995 Sep 15;123(6):415-20
references.pmid: 7639440
references.citation: Rev Inst Med Trop Sao Paulo. 2001 Sep-Oct;43(5):243-6
references.pmid: 11696844
references.citation: Semin Pediatr Infect Dis. 2006 Jul;17(3):149-52
references.pmid: 16934709
references.citation: Mem Inst Oswaldo Cruz. 2011 Mar;106(2):119-22
references.pmid: 21537668
references.citation: BMC Infect Dis. 2012 Oct 26;12:273
references.pmid: 23101431
references.citation: J Antimicrob Chemother. 2010 Sep;65(9):1907-14
references.pmid: 20584746
references.citation: Clin Infect Dis. 2002 Jan 15;34(2):184-90
references.pmid: 11740706
references.citation: Rev Bras Ginecol Obstet. 2012 Dec;34(12):544-9
references.pmid: 23329283
references.citation: J Microbiol Immunol Infect. 2004 Jun;37(3):169-75
references.pmid: 15221037
references.citation: Mol Microbiol. 2004 Oct;54(1):23-31
references.pmid: 15458402
references.citation: Int J Clin Exp Pathol. 2013 Jul 15;6(8):1693-5
references.pmid: 23923091
references.citation: Medicina (B Aires). 2005;65(3):201-6
references.pmid: 16042129
references.citation: Vaccine. 2013 Aug 28;31 Suppl 4:D43-5
references.pmid: 23973346
references.citation: Lancet. 2012 Feb 11;379(9815):547-56
references.pmid: 22226047
references.citation: J Med Microbiol. 2011 Feb;60(Pt 2):230-235
references.pmid: 21030500
references.citation: Clin Infect Dis. 2005 Sep 15;41(6):839-47
references.pmid: 16107984
references.citation: Ginecol Obstet Mex. 2006 Mar;74(3):139-43
references.pmid: 16886755
references.citation: BMC Infect Dis. 2006 Mar 20;6:57
references.pmid: 16549015
references.citation: MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36
references.pmid: 21088663
references.citation: Antimicrob Agents Chemother. 2011 Jun;55(6):2983-5
references.pmid: 21383092